期刊
CURRENT OPINION IN CHEMICAL BIOLOGY
卷 68, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2022.102148
关键词
BET; Bromodomain; BRD4; JQ1; PROTAC
资金
- Structural Genomics Consortium (SGC) - Bayer AG [424228829]
- Boehringer Ingelheim
- Bristol Myers Squibb
- Genentech
- Genome Canada through Ontario Genomics Institute
- EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [1097737]
- Janssen
- Merck KGaA
- Pfizer
- Takeda
- German Cancer Research Center (DKTK)
- Frankfurt Cancer Institute (FCI)
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [875510]
Lysine acetylation creates docking sites for epigenetic reader domains of BET bromodomain proteins, which are important regulators of linage specific gene transcription. The development of potent and selective inhibitors has facilitated mechanistic studies in disease models and translation into clinical practice. Advances in pan-BET inhibitors have led to second generation inhibitors with improved selectivity, as well as highly potent bifunctional and dual inhibitors, expanding the toolbox for research on acetylation dependent transcription, BET-associated diseases, and epigenetic reader domains.
Lysine acetylation creates docking sites for epigenetic reader domains of BET bromodomain proteins that have emerged as principal regulators of linage specific gene transcription. The development of potent and highly selective inhibitors, that have been soon widely available, enabled mechanistic studies in a diversity of disease models leading to a rapid translation into the clinic. Initial studies on pan-BET inhibitors lead now to second generation inhibitors with improved domain selectivity, but also to highly potent bifunctional and dual inhibitors extending the toolbox for basic research on acetylation dependent transcription, BET associated diseases and further translational efforts targeting this interesting family of epige-netic reader domains.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据